A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

被引：0
|
作者：
Gort, Eelke
Johnson, Melissa Lynne
Hwang, Jimmy J.
Pant, Shubham
Dunzinger, Ulrich
Riemann, Kathrin
Kitzing, Thomas
Janne, Pasi A.
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Levine Canc Inst, Charlotte, NC USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Biberach, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3651
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.
    Adjei, A. A.
    Sosman, J. A.
    Dy, G. K.
    Ma, W.
    Fetterly, G. J.
    Skupien, D.
    Means, J. A.
    Savage, R.
    Chai, F.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] TRIAL IN PROGRESS: PHASE I DOSE-ESCALATION STUDY OF VSV-GP (BI 1831169) MONOTHERAPY AND WITH EZABENLIMAB (BI 754091) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Porosnicu, Mercedes
    Quinson, Anne-Marie
    MacKay, Abi
    Luecke, Stephan
    Lauer, Ulrich M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A660 - A660
  • [23] CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.
    Mooradian, Meghan
    Cleary, James M.
    Cohen, Justine Vanessa
    Lawrence, Donald P.
    Buchbinder, Elizabeth Iannotti
    Giobbie-Hurder, Anita
    Parikh, Aparna Raj
    Shapiro, Geoffrey
    Darville, Lancia
    Smalley, Keiran
    Koomen, John M.
    Newton, Amber
    Keer, Harold N.
    Ivy, S. Percy
    Chen, Helen X.
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
    Kollmannsberger, C.
    Hirte, H.
    Siu, L. L.
    Mazurka, J.
    Chi, K.
    Elit, L.
    Walsh, W.
    Sederias, J.
    Doyle, A.
    Eisenhauer, E. A.
    Oza, A. M.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 238 - 244
  • [25] Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Dong, Xiaorong
    Wang, Huijuan
    Yuan, Ying
    Yu, Yan
    Zhang, Meijiang
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Véronique Diéras
    Thomas Bachelot
    Mario Campone
    Nicolas Isambert
    Florence Joly
    Christophe Le Tourneau
    Philippe Cassier
    Emmanuelle Bompas
    Pierre Fumoleau
    Sabine Noal
    Christine Orsini
    Marta Jimenez
    Diane Charlotte Imbs
    Etienne Chatelut
    Oncology and Therapy, 2016, 4 (2) : 211 - 223
  • [27] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Dieras, Veronique
    Bachelot, Thomas
    Campone, Mario
    Isambert, Nicolas
    Joly, Florence
    Le Tourneau, Christophe
    Cassier, Philippe
    Bompas, Emmanuelle
    Fumoleau, Pierre
    Noal, Sabine
    Orsini, Christine
    Jimenez, Marta
    Imbs, Diane Charlotte
    Chatelut, Etienne
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 211 - 223
  • [28] An Open-label Phase 1 Dose-escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
    Marconato, L.
    Finotello, R.
    Bonfanti, U.
    Dacasto, M.
    Beatrice, L.
    Pizzoni, S.
    Leone, V. F.
    Balestra, G.
    Furlanello, T.
    Bley, C. Rohrer
    Aresu, L.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (02): : 620 - 625
  • [29] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [30] A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
    Isambert, Nicolas
    Elez, Elena
    Zanetta, Sylvie
    Matos, Ignacio
    Nazabadioko, Serge
    Xue, Wenqiong
    Carriere, Philippe
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345